SEC Form 4 · accession 0001179110-15-009320
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank E Thomas
Officer — President & COO
Period of report
Jun 4, 2015
Accepted (ET)
Jun 8, 2015 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 4, 2015 | S | 12,004 | $69.27 | D | 117,305 | D | |
| Common StockF2 | Jun 4, 2015 | S | 7,996 | $69.76 | D | 109,309 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $68.57 to $69.55, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- F2The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $69.58 to $70.21, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.